Eli Lilly says next-generation weight loss drug clears crucial obesity trial

Eli Lilly announces that its next-generation weight loss drug retatrutide has successfully passed a crucial obesity trial. The injection works through a different mechanism than existing weight loss treatments and brings the company closer to filing for regulatory approval.